Two classes of medications designed as novel therapeutic strategies for DM2, namely Glucagon-Like Peptide-1 receptor agonists (GLP-1Ra) and Sodium-glucose cotransporter-2 inhibitors (SGLT2i), have demonstrated to reduce CV mortality and the occurrence of heart failure (HF) in patients with DM2 [8,9,10]
Ann Neurol 92(2):230245
Fujita Y, Yoshioka N, Abe R, Murata J, Hoshina D, Mae H, Shimizu H (2011) Rapid immunochromatographic test for serum granulysin is useful for the prediction of Stevens-Johnson syndrome and toxic epidermal necrolysis
Living with the relentless brain fog, profound fatigue, and unpredictable symptoms of Long COVID, ME/CFS, or dysautonomia can feel like an endless battle against your own biology